All In Biotech

Drug Trial Radar · NCT03125642

Auto Stem Cell Transplant for Lymphoma Patients

Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Apr 20, 2017

Primary completion

Sep 30, 2027

Study completion Apr 30, 2028

Sponsor

Lead sponsor
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 24, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II study of autologous transplant for patients with Hodgkin (HL) and non-Hodgkin lymphomas (NHL) including those who are HIV positive.

Conditions

  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma

Interventions

  • EtoposideDrug

    BEAM: 100 mg/m\^2 IV over 2 hours BID on Days -5, -4, -3, -2 \| CBV: 150 mg/m\^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4

  • BCNUDrug

    BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6

  • AraCDrug

    BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2

  • MelphalanDrug

    BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1

  • Peripheral blood stem cell transplantationProcedure

    All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.

  • G-CSFBiological

    All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3

  • CyclophosphamideDrug

    CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6

  • Total Body IrradiationRadiation

    CY/TBI: 165 cGy bid on Day -4, -3, -2, -1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival ComparisonTime frame: 3 years post transplant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Masonic Cancer Center, University of Minnesota

    Minneapolis, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.